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A. fumigatus to 2-drug combination of ABLC, L-AMB 
or C-AMB with CFG and MFG was evaluated by the 
fractional inhibitory concentration index (FICI) 
method. The FICI was determined by a 2-dimensional 
checker-board using the M38-P broth microdilution 
technique proposed by the National Committee for 
Clinical Laboratory Standards for MIC testing of 
conidium-forming filamentous fungi except that the 
MIC was defined as the concentration of the drug that 
provided no visible growth as determined by the 
reduction of tetrazolium compound (MTT assay). The 
FICI was calculated by the formula: FICI=(A, ( 
A,)+(B,tB ) h a w ere A, and B, are the MICs of drugs A 
and B in combination and A, and B, are the MICs of 
drugs A and B. The drug interactions were classified as 
synergistic (FICI<O.S), additive (FICI>O.S but 11) 
indifferent (FICI>l but 12) and antagonistic (FICI>2). 
The FICIs obtained for six two-drug combinations were 
as follows: AMB+CFG=0.42+0.12, ABLC+CFG= 
0.33+0.15, L-AMB+CFG=0.51+0.10, AMB+MFG= 
0.51r0.11, ABLC +MFG=0.47+0.15 and L-AMB+ 
MFG=0.43 kO.14 indicating synergistic interactions in all 
six combinations. These in vitro data suggest that 
conventional and lipid formulations of amphotericin B in 
2-drug combination with the echinocandin caspofungin or 
micafungin is synergistically active against A. fumigatus. 
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Chronic granulomatous disease (CGD) is a rare in- 
herited disorder of the NADPH oxidase complex 
in which neutrophils and monocytes fail to generate 
reactive oxidants such as superoxide anion and hydrogen 
peroxide, key elements in host defense against a variety 
of bacterial and fungal pathogens. 
The overall incidence of fungal infections in CGD has 
been reported at least 20%, with Aspergillus spp. being 
responsible for 78% of all fungal infections. Aspergillosis 
is the most common cause of mortality in these patients 
being responsible for over one third of deaths. Although 
Aspergillus fumigatus is by far the most frequent fungus 
causing infections in immunocompromised patients, A. 
nidulans has also been recognized as a human pathogen. 
Osteomyelitis has occurred in 25% of patients with 
CGD. Aspergillus spp. are the second most common 
cause accounting for approximately 22% of all osteo- 
myelitis cases as recorded in the USA registry. 
We recently treated a CGD patient with femoral 
osteomyelitis due to A. nidulans who had a favorable 
outcome. We review the reported cases of osteomyelitis 
in CGD patients due to this organism and we compare 
them with those due to A. fumigatus. 
Twenty cases of A. nidulans infections have been 
reported in CGD patients to date. In the great majority, 
lungs have been involved, whereas in some patients, 
expansion to neighboring tissues or to remote areas has 
taken place. Fifteen cases of osteomyelitis due to A. 
nidulans have been described in patients with CGD. All 
of them have been males and associated with simul- 
taneous pulmonary infection except for our case. 
Vertebrae and ribs have been found as the sites most 
commonly affected mainly as a result of rapid con- 
tiguous spread from a pulmonary focus. The outcome 
has been generally poor with a mortality rate approach- 
ing 50%. The commonest genetic pattern has been X- 
linked CGD gp91-phox-deficient (60% of 15 cases). 
The management of these cases has been problematic. 
Treatment has required a combined approach with 
surgical debridement, because of the persistent nature of 
the organism, and administration of intensive and pro- 
longed antifungal therapy with amphotericin-B (AMB) 
in the great majority of cases. The addition of a colony- 
stimulating factor or interferon-gamma has appeared to 
have catalytic role in the treatment of these infections. 
By comparison, osteomyelitis due to A. fumigatus has 
been reported in 8 male CGD patients to date.There has 
been no predilection for particular bones; tibia, femur, 
spine and cranium have been some examples. At least 
two multifocal osteomyelitis cases have been described. 
In all cases the outcome has been favourable. However, 
in most of them treatment has required a combined 
approach with surgical debridement and AMB. In some 
cases, interferon-gamma has also been used. 
In conclusion, overall A. fumigatus has been a more 
common pathogen compared with A. nidulans in CGD, 
but A. nidulans has been more virulent and significantly 
more likely to result in death, to involve adjacent bones 
and to cause disseminated disease compared to A. 
fumigatus. Patients with A. nidulans osteomyelitis have 
received longer courses of AMB therapy compared to 
patients with A. fumigatus osteomyelitis. Surgical 
debridement appears to be necessary, but especially in 
A. nidulans osteomyelitis early surgery is imperative. 
Adjunctive use of cytokines in both A. nidulans and A. 
fimigatus osteomyelitis seems to be successful. This 
comparison shows that A. nidulans osteomyelitis carries 
more severe implications than that of A. fumigatus and 
needs more aggressive therapy. 
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Intravenous itraconazole has been approved for second 
line therapy of invasive pulmonary aspergillosis. How- 
ever, little is known about its comparative antifungal 
efficacy against this disease in the state of persistent and 
profound neutropenia. We therefore investigated the 
pharmacokinetics and pharmacodynamics of intra- 
venous hydroxypropyl-beta-cyclodextrin itraconazole in 
a persistently neutropenic rabbit model of invasive 
pulmonary aspergillosis. 
Twenty-four hours following endotracheal inoculation 
with Aspergillus jumigatus, cohorts of 4 animals each 
received itraconazole at dosages ranging from 0.66 to 16 
mg/kg once daily as lo-minutes IV bolus for a total of 12 
days. Optimal plasma sampling was performed in each 
individual animal after the 5th dose to obtain pharma- 
cokinetic and pharmacodynamic parameters. Untreated 
animals and animals treated with standard amphotericin 
B deoxycholate (lmg/kg) served as controls. Responses 
to treatment were evaluated by survival and the residual 
fungal burden in lung tissue at autopsy. 
Intravenous itraconazole showed dose-dependent anti- 
fungal efficacy against invasive pulmonary aspergillosis. 
The relationship between dosage and residual fungal 
burden in lung tissue followed an inhibitory effect 
sigmoidal Emax function with an estimated ED50 of 7 
mg/kg. In comparison to untreated controls, treatment 
with dosages of 6.6 to 12 mg/kg resulted in a reduction 
of the residual fungal burden in lung tissue (p<O.OOOl) 
and improved survival (p ~0.001). Pharmacodynamic 
modeling revealed significant relationships between 
pharmacodynamic parameters, the residual fungal 
burden in lung tissue, and survival. Itraconazole was well 
tolerated without renal or hepatic laboratory abnor- 
malities. Acute dose-limiting neurological toxicity 
(seizures) occurred at 16mg/kg (2 animals). 
In conclusion, IV itraconazole displayed dose- 
dependent antifungal efficacy in a clinically relevant 
persistently neutropenic animal model of pulmonary 
aspergillosis. 
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Candida albicans is a polymorphic fungus that can 
switch between blastospores, pseudohyphae, and true 
hyphae. All three morphologic forms are frequently 
recovered from tissues of patients with disseminated 
candidiasis and are therefore important in the patho- 
genicity of C. albicans. Previously we cloned the 
Agglutinin-Like Sequence 1 (ALU) gene, which 
encodes a candidal cell surface protein. We demon- 
strated that Alsl protein (Alslp) is required for 
adherence to endothelial cells, and virulence in a mouse 
model of hematogenously disseminated candidiasis. 
To investigate the feasibility of using Alslp in vaccine 
strategies to protect against hematogenously dissemi- 
nated candidiasis, we studied the expression of ALSl in 
the three different morphologies of C. albicans. The 
expression of ALU was determined by Northern 
blotting, and confocal immunofluorescence microscopy 
using an ALSI specific probe and monoclonal antibody 
raised against the N-terminus of Alslp, respectively. 
RNA expression of ALSI was detected in all forms of 
C. albicans with maximal expression during lag phase of 
growth. Although Alslp was expressed during all 
polymorphic forms of C. albicans, localization of the 
protein on the cell surface was altered among these 
phases. Diffused staining was detected on the surface of 
blastospores. When cells were grown as pseudohyphae, 
Alslp expression was detected along the entire 
pseudohyphus. In contrast, in true hyphae, Alslp staining 
was most intense at the base of the emerging hyphae. 
The detection of Alslp expression on the cell surface 
during all three forms of C. albicans growth will prove 
to be beneficial in exploiting this protein to develop 
vaccine strategies against mucosal and disseminated 
candidiasis. 
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Introduction: Infections by filamentous fungi, parti- 
cularly Aspergillus spp., are increasing in incidence in 
immunocompromised patients and are associated with 
high morbidity and mortality. IL-15 is a Thl cytokine 
associated with the innate immune response, which has 
various enhancing effects on phagocytic function. IL-8 
is a potent chemokine and TNF-alpha has broad pro- 
inflammatory properties. We hypothesised that IL-15 
plays a role in modulation of the release of these two 
cytokines in response to Aspergillus spp. 
Methods: Polymorphonuclear leukocytes (PMNLs) 
were isolated by dextran sedimentation/ficoll centri- 
fugation from blood obtained from healthy adult donors. 
Following pre-treatment of PMNLs with or without 100 
rig/ml IL-15 for 22 hours, untreated and IL-15 treated 
PMNLs (1.5~ 10s/well) were incubated for 4 hours in 
HBSS, either unchallenged or challenged with hyphae of 
Aspergillus fumigatus, Aspergillus flavus or Verticillium 
nigrescens, a fungus of low pathogenicity, at E:T ratio 
